Contineum Therapeutics Reports Third-Quarter 2026 Financial Results
Yahoo Finance · Nov 3, 2026 · Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
SAN DIEGO, November 03, 2026--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results.
Not investment advice. Headline and summary only, not a full reprint.